TY - JOUR
T1 - Prevalence of neurocognitive and perceived speech deficits in patients with head and neck cancer before treatment
T2 - Associations with demographic, behavioral, and disease-related factors
AU - Piai, Vitória
AU - Jansen, Femke
AU - NET-QUBIC consortium
AU - Dahlslätt, Kristoffer
AU - Verdonck-de Leeuw, Irma M.
AU - Prins, Judith
AU - Leemans, René
AU - Terhaard, Chris H. J.
AU - Langendijk, Johannes A.
AU - Baatenburg de Jong, Robert J.
AU - Smit, Johannes H.
AU - Takes, Robert
AU - P. C. Kessels, Roy
N1 - Funding Information: This work was supported by the Dutch Cancer Society (KWF‐Alpe d'Huzes, to NET‐QUBIC Consortium). Publisher Copyright: © 2021 The Authors. Head & Neck published by Wiley Periodicals LLC.
PY - 2021
Y1 - 2021
N2 - Background: Neurocognition and speech, relevant domains in head and neck cancer (HNC), may be affected pretreatment. However, the prevalence of pretreatment deficits and their possible concurrent predictors are poorly understood. Methods: Using an HNC prospective cohort (Netherlands Quality of Life and Biomedical Cohort Study, N ≥ 444) with a cross-sectional design, we investigated the estimated prevalence of pretreatment deficits and their relationship with selected demographic, behavioral, and disease-related factors. Results: Using objective assessments, rates of moderate-to-severe neurocognitive deficit ranged between 4% and 8%. From patient-reported outcomes, 6.5% of patients reported high levels of cognitive failures and 46.1% reported speech deficits. Patient-reported speech functioning was worse in larynx compared to other subsites. Other nonspeech outcomes were unrelated to any variable. Patient-reported neurocognitive and speech functioning were modestly correlated, especially in the larynx group. Conclusions: These findings indicate that a subgroup of patients with HNC shows pretreatment deficits, possibly accentuated in the case of larynx tumors.
AB - Background: Neurocognition and speech, relevant domains in head and neck cancer (HNC), may be affected pretreatment. However, the prevalence of pretreatment deficits and their possible concurrent predictors are poorly understood. Methods: Using an HNC prospective cohort (Netherlands Quality of Life and Biomedical Cohort Study, N ≥ 444) with a cross-sectional design, we investigated the estimated prevalence of pretreatment deficits and their relationship with selected demographic, behavioral, and disease-related factors. Results: Using objective assessments, rates of moderate-to-severe neurocognitive deficit ranged between 4% and 8%. From patient-reported outcomes, 6.5% of patients reported high levels of cognitive failures and 46.1% reported speech deficits. Patient-reported speech functioning was worse in larynx compared to other subsites. Other nonspeech outcomes were unrelated to any variable. Patient-reported neurocognitive and speech functioning were modestly correlated, especially in the larynx group. Conclusions: These findings indicate that a subgroup of patients with HNC shows pretreatment deficits, possibly accentuated in the case of larynx tumors.
KW - fluency
KW - head and neck cancer
KW - neurocognitive assessment
KW - pretreatment symptoms
UR - http://www.scopus.com/inward/record.url?scp=85119499656&partnerID=8YFLogxK
U2 - https://doi.org/10.1002/hed.26930
DO - https://doi.org/10.1002/hed.26930
M3 - Article
C2 - 34799885
SN - 1043-3074
JO - Head and Neck
JF - Head and Neck
ER -